Corpus Intelligence IC Memo — CLEARFIELD HOSPITAL 2026-04-26 15:53 UTC
IC Memo — CLEARFIELD HOSPITAL
Investment Committee Memorandum | PA | 40 beds | Grade C | EBITDA uplift $3.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CLEARFIELD HOSPITAL

CCN 390052 | CLEARFIELD, PA | 40 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CLEARFIELD HOSPITAL is a 40-bed rural/critical access in CLEARFIELD, PA with $42.7M in net patient revenue and a -2.6% operating margin. The hospital serves a payer mix of 42.7% Medicare, 1.1% Medicaid, and 56.2% commercial.

Thesis: Turnaround. Our ML models identify $3.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -2.6% to 4.7% (+736bps).

Net Revenue HCRIS$42.7M
Current EBITDA COMPUTED$-1.1M
Operating Margin COMPUTED-2.6%
Occupancy HCRIS25.6%
Revenue / Bed COMPUTED$1.1M
Net-to-Gross HCRIS30.6%
Distress Probability ML53.8%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
81
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -2.6% places it above the state median. Among 81 size-comparable peers (20-80 beds), the median margin is 1.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (20-80), prioritizing same-state peers. 81 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CLEARFIELD HOSPITAL (Target)PA40$42.7M-2.6%
THE GETTYSBURG HOSPITALPA76$341.8M18.4%
UPMC HANOVERPA73$200.8M18.2%
MEMORIAL HOSPITALPA80$184.5M13.1%
UPMC CARLISLEPA72$165.0M19.5%
OSS ORTHOPAEDIC HOSPITALPA30$149.4M-5.0%
WELLSPAN SURGERY AND REHAB HOSPA25$120.2M2.8%
UPMC LITITZPA36$114.5M14.2%
MINERS MEMORIAL MEDICAL CENTERPA49$107.7M12.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$897K+210bp18mo
Cost to Collect4.5%2.5%$854K+200bp12mo
Denial Rate Reduction12.0%6.5%$845K+198bp12mo
A/R Days Reduction5200.0%3800.0%$520K+122bp9mo
Clean Claim Rate88.0%96.0%$27K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$897K
Cost to Collect
$854K
Denial Rate Reduction
$845K
A/R Days Reduction
$520K
Clean Claim Rate
$27K
Total EBITDA Uplift$3.1M
Current EBITDA$-1.1M
+ RCM Uplift+$3.1M
Pro Forma EBITDA$2.0M
Current Margin-2.6%
Pro Forma Margin4.7%
WC Released (1x)$1.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-1.7M$24.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-1.7M$25.8M0.00x-100.0%
Bull Case9.0x11.0x$-1.6M$35.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-1.6M$38.4M0.00x-100.0%
Bear Case11.0x10.0x$-1.9M$8.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-1.9M$9.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 25.6%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 53.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 81 hospitals with 20-80 beds
  • Same-state prioritization (n=82)
  • Comp margins: P25=-12.8% / P50=1.8% / P75=9.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.